- Zacks•2 days ago
Biotech major, Amgen, Inc. (AMGN), announced that its multiple myeloma drug Kyprolis did not meet the primary endpoint in a phase III head-to-head CLARION study with Velcade.
- Investor's Business Daily•3 days ago
Amgen's multiple myeloma drug failed its primary endpoint Tuesday, sending shares into a skid.
Ligand Pharmaceuticals Incorporated (LGND)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||85.00 x 500|
|Day's Range||100.76 - 102.49|
|52wk Range||81.79 - 139.79|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||9.62|
|Avg Vol (3m)||445,940|
|Dividend & Yield||0.00 (0.00%)|